| Cat.No. | Name | Information |
|---|---|---|
| M1721 | AZD4547 | AZD4547 (Fexagratinib) is a potent, selective and orally active pan-FGFR inhibitor with IC50s of 0.2. 2.5, 1.8 and 165 nM for FGFR1, 2, 3 and 4, respectively. |
| M1840 | BGJ398 (Infigratinib) | BGJ398 (Infigratinib) is a potent and selective FGFR kinase inhibitor with IC50 values of 0.9 nM, 1.4 nM, 1 nM and 60 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. |
| M9715 | Erdafitinib | Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. |
| M1875 | PD173074 | PD173074 is a selective FGFR1 and FGFR3 inhibitor with IC50 values of 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively. |
| M40899 | LOXO-435 | LOXO-435 is a highly selective fibroblast growth factor receptor-3 (FGFR3) antagonist that can be used in a variety of tumor-related studies. |
| M30269 | Surfen dihydrochloride | Surfen dihydrochloride is a potent HS (heparan sulfate) antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins. Surfen affects sulfation of heparin and inhibits degradation by heparin lyases. Surfen inhibits FGF2 binding and signaling. Surfen inhibits cell attachment, and virus infection. |
| M28979 | E7090 succinate | E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. |
| M28863 | PD-089828 | PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity. |
| M28710 | E7090 | E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively. |
| M24907 | Pegbelfermin | Pegbelfermin (BMS-986036) is a polyethylene glycol-modified (PEGylated) analogue of human fibroblast growth factor 21 (FGF21). Pegbelfermin can be used for the research of nonalcoholic steatohepatitis (NASH). |
| M24606 | Vofatamab | Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
| M20223 | WAY-625530 | WAY-625530 is a Fibroblast Growth Factor Receptor 1 Kinase inhibitor. |
| M20221 | WAY-621856 | WAY-621856 is a FGFR inhibitor. |
| M20193 | WAY-603814 | WAY-603814 is a FGFR1 inhibitor |
| M20183 | WAY-600868 | WAY-600868 is a FGFR3 inhibitor. |
| M20165 | WAY-353890 | WAY-353890 is a inhibitor of protein kinase FGFR1 |
| M20050 | WAY-272449 | WAY-272449 is a FGFR1 inhibitor. |
| M20048 | WAY-272130 | WAY-272130 is a FGFR1 inhibitor. |
| M20039 | WAY-270599 | WAY-270599 is a FGFR1 inhibitor |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
